NasdaqGS:MYGNBiotechs
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns
Q1 2026 earnings snapshot
Myriad Genetics (MYGN) reported Q1 2026 revenue of US$200.4 million with a basic EPS loss of US$0.36, setting the tone for another quarter where the focus is firmly on profitability rather than top line scale. Over the past year, the company has seen quarterly revenue move within a tight band from US$195.9 million in Q1 2025 to US$213.1 million in Q2 2025, while basic EPS has ranged from a small loss of roughly US$0.00 in Q1 2025 to a loss of US$3.57 in Q2 2025. With...